NCT05089565View on ClinicalTrials.gov

Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions
SarcoidosisSARS-CoV2 InfectionVaccine Response Impaired
Interventions
DIAGNOSTIC_TEST

Assay of (1) the level of anti-spike IgG antibody, and (2) interferon-gamma release in response to SARS-CoV-2 antigen stimulation

Measurement of humeral and cell-mediated immune responses to SARS-CoV-2 vaccination

Trial Locations (1)

60611

Northwestern Medicine, Chicago

All Listed Sponsors
collaborator

Foundation for Sarcoidosis Research

OTHER

lead

Northwestern University

OTHER

NCT05089565 - Immune Response to SARS-CoV-2/COVID-19 Vaccination in Sarcoidosis | Biotech Hunter | Biotech Hunter